Did you know? Psoriasis can put you at type 2 diabetes risk
December 18, 2018
Comparative Effectiveness of Biologic Agents in Rheumatoid Arthritis Examined
December 20, 2018
Show all

Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis

Abatacept reduced the risk for diabetes in patients with rheumatoid arthritis.

The use of the disease-modifying antirheumatic drug (DMARD) abatacept could lead to a reduction in the risk for diabetes in patients with rheumatoid arthritis (RA), according to a study presented at the 2018 ACR/ARHP Annual Meeting, October 19-24, in Chicago, Illinois.

Researchers in this retrospective study analyzed data from the Truven Marketscan database to group patients with RA by the DMARD they were using for treatment: abatacept, infliximab, adalimumab, golimumab, certolizumab, etanercept, tocilizumab, or tofacitinib.

The researchers followed the participants until they were diagnosed with diabetes or reached the end of the 10-year study. For outcome purposes, they performed an analyses with the entire study group divided into new biologic initiators, which were patients who were biologic treatment naive (n=56,014), or biologic switchers, which were patients who changed biologic treatments (n=27,152).

The study population had an average age of 50 years, was about 75% female, and used infliximab, adalimumab, and etanercept treatments most frequently. Overall, there were 335 new cases of diabetes in the new biologic initiator group and 155 in the biologic switchers group.

Read on: Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.